Eisai Co Ltd (ESALF)
OTHER OTC:ESALF
Want to see ESALF full AI Analyst Report?
ESALF Stock Chart & Stats
$30.44
-$1.06(-3.81%)
At close: 4:00 PM EST
$30.44
-$1.06(-3.81%)
Day’s Range― - ―
52-Week Range$24.05 - $36.46
Previous CloseN/A
Volume500.00
Average Volume (3M)151.00
Market Cap
$7.36B
Enterprise Value$1.11T
Total Cash (Recent Filing)$245.42B
Total Debt (Recent Filing)$186.08B
Price to Earnings (P/E)35.6
Beta0.50
Next Earnings
Jul 31, 2026EPS Estimate
0.4Next Dividend Ex-DateN/A
Dividend Yield3.62%
Share Statistics
EPS (TTM)136.74
Shares Outstanding291,649,140
10 Day Avg. Volume127
30 Day Avg. Volume151
Financial Highlights & Ratios
PEG Ratio-2.16
Price to Book (P/B)1.53
Price to Sales (P/S)1.66
P/FCF Ratio29.87
Enterprise Value/Market Cap151.30
Enterprise Value/Revenue1.35
Enterprise Value/Gross Profit1.76
Enterprise Value/Ebitda13.18
Forecast
1Y Price Target
$31.41Price Target Upside3.17% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)1.34
Revenue Forecast (FY)$5.55B
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained gross margins in the mid-70s to ~80% reflect durable pricing power in specialty pharma and manufacturing efficiency. This margin buffer supports reinvestment in R&D and commercial activities and helps absorb cost pressures without immediate profit erosion.
Conservative Balance SheetLow and improving leverage with growing equity enhances financial flexibility for multi-year drug development cycles. A conservative capital structure reduces refinancing risk, supports steady investment in pipelines and partnerships, and underpins dividend and partnership obligations.
Revenue Growth And Partnered FranchiseAn improving top-line trajectory plus collaboration-driven revenue (notably the Alzheimer's partnership) provides diversified, multi-year revenue streams. Partner economics reduce single-product commercialization risk and enable shared development and market access investments.
Bears Say
Eroding Net MarginsDeclining bottom-line margins from prior peaks indicate pressure on profitability possibly from higher SG&A, launch costs or adverse product mix. Persistently lower net margins reduce retained earnings for growth and make returns more sensitive to revenue volatility.
Cash Flow VolatilityYear-to-year swings in operating and free cash flow signal execution and timing risk for funding R&D, M&A or dividends. A sharp recent FCF decline increases reliance on financing or asset-sales during stress, limiting consistent multi-year investment planning.
Moderate Return On EquityMid-single-digit ROE points to modest efficiency in converting equity into profits. Over time, moderate returns can cap shareholder value creation versus peers, requiring higher growth or margin expansion to meaningfully improve investor returns.
Eisai Co News
ESALF FAQ
What was Eisai Co Ltd’s price range in the past 12 months?
Eisai Co Ltd lowest stock price was $24.05 and its highest was $36.46 in the past 12 months.
What is Eisai Co Ltd’s market cap?
Eisai Co Ltd’s market cap is $7.36B.
When is Eisai Co Ltd’s upcoming earnings report date?
Eisai Co Ltd’s upcoming earnings report date is Jul 31, 2026 which is in 68 days.
How were Eisai Co Ltd’s earnings last quarter?
Eisai Co Ltd released its earnings results on May 15, 2026. The company reported -$0.072 earnings per share for the quarter, missing the consensus estimate of $0.078 by -$0.15.
Is Eisai Co Ltd overvalued?
According to Wall Street analysts Eisai Co Ltd’s price is currently Undervalued.
Does Eisai Co Ltd pay dividends?
Eisai Co Ltd pays a Semiannually dividend of $0.509 which represents an annual dividend yield of 3.62%. See more information on Eisai Co Ltd dividends here
What is Eisai Co Ltd’s EPS estimate?
Eisai Co Ltd’s EPS estimate is 0.4.
How many shares outstanding does Eisai Co Ltd have?
Eisai Co Ltd has 291,649,140 shares outstanding.
What happened to Eisai Co Ltd’s price movement after its last earnings report?
Eisai Co Ltd reported an EPS of -$0.072 in its last earnings report, missing expectations of $0.078. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Eisai Co Ltd?
Currently, no hedge funds are holding shares in ESALF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Eisai Co Ltd
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
ESALF Company Deck
ESALF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a strong performance of their global brands and significant global expansion of LEQEMBI, contributing to positive revenue growth. However, challenges in controlling cost of sales, slower-than-expected U.S. market expansion, and concerns about competitive threats were notable downsides.View all ESALF earnings summariesESALF Stock 12 Month Forecast
Average Price Target
$31.41
▲(3.17% Upside)
Technical Analysis
Sumitomo Dainippon Pharma Co
―
Kaken Pharmaceutical Co
―
Shionogi & Co
―
Takeda Pharmaceutical Co
―
Nippon Shinyaku Co., Ltd.
―
Ownership Overview
―
Insiders
7.73% Mutual Funds
0.08% Other Institutional Investors
80.71% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---